Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 20/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 20/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240229 | 0.92 | MAPK11 (0.48) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243524 | 0.90 | MAPK14 (0.51) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL245051 | 0.87 | MAPK11 (0.51) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243655 | 0.84 | MAPK14 (0.51) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL239890 | 0.84 | BRD4 (0.61) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL244250 | 0.83 | MAPK14 (0.52) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243394 | 0.83 | MAPK14 (0.58) | MAPK11MAPK14 | |
| SCHEMBL242779 | 0.79 | KMT2A (0.55) | MAPK11MAPK14 | |
| SCHEMBL2904542 | 0.79 | MAPK11 (0.52) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243053 | 0.78 | MAPK11 (0.52) | MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2013-02-07 | — | — | US | claimed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | claimed |
| CN-1918134-B | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | CN | claimed |
| EP-1699766-B1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | claimed |
| JP-2007516979-A | — | — | 2007-06-28 | — | — | JP | claimed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| CN-1918134-A | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | claimed |
| EP-1699766-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | claimed |
| WO-2005061465-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| US-8742124-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2014-06-03 | — | — | US | disclosed |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2013-02-07 | — | — | US | disclosed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | disclosed |
| US-7943776-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| CN-1918134-B | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | CN | disclosed |
| EP-1699766-B1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| CN-1918134-A | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1699766-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061465-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | IL2, IL6, IL1B | MAPK11 2179/4885MAPK14 1549/4885MAPK13 2573/4885 |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | MAPK11 2262/4885MAPK14 1594/4885MAPK13 2611/4885 |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | MAPK11 2262/4885MAPK14 1594/4885MAPK13 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.